+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Significant Drug Launches in 2019: A Research Analysis and Insights on Pharmaceutical Industry

  • ID: 4846707
  • Report
  • September 2019
  • Region: Global
  • 127 pages
  • BCC Research
1 of 5

FEATURED COMPANIES

  • Abbvie Inc.
  • Aimmune Therapeutics Inc.
  • Bluebird Bio Inc.
  • Celgene Corp.
  • Gilead Sciences Inc.
  • Novartis Ag
  • MORE
Report Scope:

The current report provides details about drug molecules that have been or will be launched in the market in 2019. This report highlights information and insights on the molecules. The report includes drug overviews, mechanisms of action, disease backgrounds, currently available treatments for diseases that these drugs address, clinical evidence on safety and efficacy, regulatory scenarios, market scope of the drugs and company profiles of manufactures.

The Report Includes:
  • Information on the top potential drug launches by pharma companies in 2019
  • Knowledge about drug, mechanism of action, and briefing of clinical evidences
  • Detailed information and insights on the drug Upadacitinib which is manufactured by AbbVie Inc. , Ultomiris (ravulizumab-cwvz) a humanized monoclonal antibody manufactured by Alexion Pharmaceuticals Inc. and many more
  • Insights into regulatory approvals, market scope, and analysis of pipeline molecules
  • Detailed profiles of the companies and competitors related to the industry
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Abbvie Inc.
  • Aimmune Therapeutics Inc.
  • Bluebird Bio Inc.
  • Celgene Corp.
  • Gilead Sciences Inc.
  • Novartis Ag
  • MORE
Chapter 1 Introduction
  • Study Goals and Objectives
  • Reasons for Doing This Study
  • Scope of Report
  • Information Sources
  • Methodology
  • Analyst's Credentials
  • Custom Research
  • Related Reports
Chapter 2 Significant Drug Launches

Chapter 3 Ultomiris (Ravulizumab)
  • Overview of Ultomiris
  • Scientific Summary
  • Pharmacodynamics and Mechanism of Action
  • Pharmacokinetics
  • Therapeutic Trials of Ultomiris on Safety and Efficacy
  • Adverse Drug Reactions
  • Disease Background
  • Epidemiology of PNH
  • Pathophysiology
  • Symptoms of PNH
  • Currently Available Treatment for PNH
  • Pipeline Molecules for PNH
  • Regulatory and Development Milestones of Ultomiris
  • Market Scope for Ultomiris
  • Current PNH Market
  • Ultomiris Market
  • Market Drivers
  • Pharmaceutical Pricing and Reimbursement
  • Ultomiris Exclusivity
  • Company Profile
  • ALEXION PHARMACEUTICALS INC.
Chapter 4 Rinvoq (Upadacitinib)
  • Drug Overview
  • Scientific Summary
  • Pharmacodynamics and Mechanism of Action
  • Pharmacokinetics
  • Therapeutic Trials of Upadacitinib on Safety and Efficacy
  • Adverse Drug Reactions
  • Disease Background
  • Epidemiology
  • Pathophysiology of RA
  • Etiology
  • Symptoms of RA
  • Unmet Needs
  • Current Available Treatment for RA
  • Pipeline Molecules
  • Regulatory Status of Upadacitinib
  • Market Scope for Upadacitinib
  • Current RA Market
  • Market Drivers
  • Upadacitinib Market
  • Company Profile
  • ABBVIE INC.
Chapter 5 Drug XX
  • Drug Overview
  • Scientific Summary
  • Mechanism of Action
  • Disease Background
  • Classification of SMA
  • Epidemiology
  • Pathophysiology
  • SMA Therapeutics Pipeline
  • Currently Available Treatment for SMA
  • Market Scope for Drug XX
  • Current SMA Market
  • Drivers for SMA Market
  • Drug XX Market
  • Company Profile
  • NOVARTIS AG
Chapter 6 Drug XX
  • Drug Overview
  • Scientific Summary
  • Mechanism of Action
  • Therapeutic Trials of Brolucizumab on Safety and Efficacy
  • Disease Background
  • Epidemiology
  • Disease Subtypes
  • Classification of AMD
  • Etiology
  • Pathophysiology
  • Unmet Needs of AMD
  • Currently Available Treatment for AMD
  • Laser Photocoagulation
  • Photodynamic Therapy
  • Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Drugs
  • Pipeline Molecules for AMD
  • Status of Regulatory Approval of Drug XX
  • Market Scope for Drug XX
  • Current Market Size of AMD
  • Market Drivers
  • Impact of Drug XX on AMD Market
  • Company Profile
Chapter 7 Drug XX
  • Drug Overview
  • Scientific Summary
  • Pharmacokinetics
  • Mechanism of Action
  • Adverse Events
  • Therapeutic Trials on Safety and Efficacy of Mayzent
  • Disease Background
  • Epidemiology
  • Pathophysiology
  • Types of MS
  • Symptoms of MS
  • Unmet Needs of MS
  • Regulatory Approval of Drug XX
  • Current Available Treatment for MS
  • Pipeline Molecules for MS
  • Market Scope for Drug XX
  • Current Multiple Sclerosis Market
  • Impact of Drug XX on MS Market
  • Company Profiles
Chapter 8 Drug XX
  • Drug Overview
  • Scientific Summary
  • Mechanism of Action
  • Pharmacokinetics
  • Therapeutic Trials on Efficacy and Safety of Risankizumab
  • Disease Background
  • Epidemiology
  • Pathophysiology
  • Types of Psoriasis
  • Regulatory and Development Milestones
  • Currently Available Treatment for Psoriasis
  • Biologics
  • Systemics
  • Phototherapy
  • Pipeline Molecules
  • Market Scope for Drug XX
  • Current Psoriasis Market
  • Drug XX Market
  • Company Profiles
Chapter 9 Drug XX
  • Drug Overview
  • Scientific Summary
  • Mechanism of Action
  • Therapeutic Trials on Safety and Efficacy of LentiGlobin
  • Disease Background
  • Epidemiology
  • Types of Thalassemia
  • Pathophysiology
  • Regulatory and Development Milestones
  • Currently Available Treatment
  • Chelating Therapy
  • Pipeline Molecules
  • Market Scope for Drug XX
  • Current Beta Thalassemia Market
  • Drug XX Market
  • Company Profile
  • BLUEBIRD BIO INC.
Chapter 10 Drug XX
  • Drug Overview
  • Scientific Summary
  • Mechanism of Action
  • Therapeutic Trials on Safety and Efficacy of Ozanimod
  • Disease Background
  • Epidemiology
  • Pathophysiology
  • Types of MS
  • Symptoms of MS
  • Unmet Needs of MS
  • Currently Available Treatment for MS
  • Pipeline Molecules of MS
  • Regulatory and Developmental Milestones
  • Market Scope for Drug XX
  • Company Profile
  • CELGENE CORP.
Chapter 11 Drug XX
  • Drug Overview
  • Scientific Summary
  • Mechanism of Action
  • Therapeutic Trials on Safety and Efficacy of AR101
  • Disease Background
  • Types of Allergic Reactions
  • Focus on Peanut Allergy
  • Management of Peanut Allergy
  • Regulatory and Development Milestones
  • Market Scope for Drug XX
  • Company Profile
  • AIMMUNE THERAPEUTICS INC.
Chapter 12 Drug XX
  • Drug Overview
  • Scientific Summary
  • Mechanism of Action
  • Therapeutic Trials on Efficacy and Safety of Filgotinib
  • Disease Background
  • Epidemiology
  • Pathophysiology of RA
  • Etiology
  • Symptoms of RA
  • Unmet Needs
  • Currently Available Treatment for Rheumatoid Arthritis
  • Pipeline Molecules
  • Market Scope for Drug XX
  • Current RA Market
  • Drug XX Market
  • Company Profile
  • GILEAD SCIENCES INC.
Chapter 13 Conclusion

Chapter 14 Appendix: Acronyms

List of Tables
Table 1: Potential Launches to Watch, 2019
Table 2: Top Companies Investing in R&D, 2018
Table 3: Potential Drug Launches, 2018
Table 4: Key Clinical Trials of Ultomiris
Table 5: Common Symptoms of PNH
Table 6: Other Pipeline Drugs for PNH
Table 7: Key Development Milestones of Ultomiris
Table 8: Alexion Pharmaceuticals Inc.: Financial Performance, 2016-2018
Table 9: Alexion Pharmaceuticals Inc.: Product Portfolio
Table 10: Alexion Pharmaceuticals Inc.: Pipeline Molecules
Table 11: Alexion Pharmaceuticals, Inc.: Recent Acquisitions
Table 12: Clinical Evidence of Safety and Efficacy of Upadacitinib
Table 13: Epidemiological Forecast for Diagnosed Prevalent Cases of Rheumatoid Arthritis, by Region, Through 2022
Table 14: Common Symptoms of RA
Table 15: Unmet Needs of RA
Table 16: Current Treatment for RA
Table 17: Pipeline Molecules for RA
Table 18: Others Pipeline Drug for JAK Inhibitors
Table 19: AbbVie, Inc.: Financial Performance, 2016-2018
Table 20: AbbVie Inc.: Product Portfolio
Table 21: AbbVie Inc.: Pipeline Molecules
Table 22: AbbVie Inc.: Recent Acquisitions
Table 23: Classification of SMA
Table 24: Milestones in Discovery of SMA
Table 25: Pipeline Molecules, SMA
Table 26: Novartis AG: Financial Performance, 2016-2018
Table 27: Novartis AG: Product Portfolio, Oncology
Table 28: Novartis AG: Product Portfolio, Ophthalmology
Table 29: Novartis AG: Product Portfolio, Immunology Hepatology and Dermatology
Table 30: Novartis AG: Product Portfolio, Neuroscience
Table 31: Novartis AG: Product Portfolio, Respiratory
Table 32: Novartis AG: Product Portfolio, Pipeline Molecules
Table 33: Novartis AG: Recent Acquisitions
Table 34: Therapeutic Trials of Brolucizumab on Safety and Efficacy
Table 35: Projected Number of People with AMD, by Region, Through 2024
Table 36: AREDS Classification of AMD
Table 37: Pipeline Molecules for AMD
Table 38: Market Size of Lucentis and Eylea, Through 2022
Table 39: Incident and Prevalent Cases of MS, by Country, 2016
Table 40: Incident and Prevalent Cases of MS, by Region, 2016
Table 41: Currently Approved Disease Modifying Therapies for MS, Injectable Treatments
Table 42: Currently Approved Disease Modifying Therapies for MS, Oral Treatments
Table 43: Currently Approved Disease Modifying Therapies for MS, Intravenous Infusion Treatments
Table 44: Pipeline Molecules for Multiple Sclerosis Showing Promising Results
Table 45: Development Milestones of Risankizumab
Table 46: Currently Available Treatment for Psoriasis, Biologics
Table 47: Pipeline Molecules in Development for Psoriasis and Related Conditions: Phase III
Table 48: Pipeline Molecules in Development for Psoriasis and Related Conditions: Phase II
Table 49: Global Psoriasis Market, by Region/Country, Through 2022
Table 50: Pipeline Molecules: Beta Thalassemia
Table 51: Bluebird Bio Inc.: Financial Performance, 2016-2018
Table 52: Bluebird Bio Inc.: Pipeline Molecules as of 2019
Table 53: Currently Approved Disease Modifying Therapies for MS, Injectable Treatments
Table 54: Currently Approved Disease Modifying Therapies for MS, Oral Treatments
Table 55: Currently Approved Disease Modifying Therapies for MS, Intravenous Infusion Treatments
Table 56: Pipeline Molecules of Multiple Sclerosis Showing Promising Results
Table 57: Development Milestones of Ozanimod as of 2019
Table 58: Celgene Corp.: Revenue Details, 2016-2018
Table 59: Celgene Corp.: Marketed Products
Table 60: Celgene Corp.: Company Agreements
Table 61: Common Symptoms of Peanut Allergy
Table 62: Common Symptoms of Rheumatoid Arthritis
Table 63: Unmet Needs of Rheumatoid Arthritis
Table 64: Current Treatment for Rheumatoid Arthritis
Table 65: Pipeline Molecules for Rheumatoid Arthritis
Table 66: Gilead Sciences Inc.: Net Revenue, 2016-2018
Table 67: Gilead Science Inc.: Marketed Products
Table 68: Gilead Science Inc.: Pipeline Molecules
Table 69: Acronyms Used in This Report

List of Figures
Figure 1: Percentage Distribution of R&D Spending for Clinical Development of Novel Drugs, by Therapeutic Category, 2019
Figure 2: Market Share Analysis of Major Players in the Global Pharmaceutical Industry, 2018
Figure 3: Soliris: Net Product Revenues, 2014-2018
Figure 4: Spinraza: Market Size, 2016-2018
Figure 5: Novartis AG: Spending on Research and Development, by Division, 2017 and 2018
Figure 6: Brolucizumab: Mechanism of Action
Figure 7: Top Eight Food Items Triggering Allergy and Number of Children Affected, 2018
Figure 8: Percentage Distribution of Drug Launches, by Therapeutic Category, 2019
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5

FEATURED COMPANIES

  • Abbvie Inc.
  • Aimmune Therapeutics Inc.
  • Bluebird Bio Inc.
  • Celgene Corp.
  • Gilead Sciences Inc.
  • Novartis Ag
  • MORE
The pharmaceutical industry aims to decrease and eliminate diseases, as well as improve the quality of life of patients who are suffering from chronic diseases. To fulfill that aim, the industry develops medicines to treat new diseases or improve upon treatments for pre-existing diseases. Pharmaceutical research is the life-blood of major research-based drug makers worldwide. The demand for novel therapeutics is increasing at an accelerated pace due to global health needs, aging and expanding populations, orphan diseases and unmet needs for many diseases. R&D facilitates the understanding of human physiology and disease mechanisms to develop new drugs or improve existing molecules.

Major pharmaceutical companies are focused on addressing the above needs, leading to the evolution of blockbuster molecules. Research and development is essential in all industries; when it comes to the biopharmaceutical research industry, R&D not only generates income for companies involved in the research, but it often saves or at least enhances patient's lives. There has been a great deal of research and development in this industry by doctors and scientists worldwide. As a result, the development of novel therapeutic options for specialties like oncology, genetic diseases, hematological diseases and immunological diseases are increasing at a great pace. Oncology holds the highest clinical development expenditure, followed by central nervous system, musculoskeletal, cardiovascular and immunomodulator disease areas.
Note: Product cover images may vary from those shown
5 of 5
  • Abbvie Inc.
  • Aimmune Therapeutics Inc.
  • Alexion Pharmaceuticals Inc.
  • Bluebird Bio Inc.
  • Celgene Corp.
  • Gilead Sciences Inc.
  • Novartis Ag
Note: Product cover images may vary from those shown
Adroll
adroll